Definition:
The Anti-Coagulants market covers drugs that prevent blood from clotting, i.e., that prolong the clotting time. Anti-coagulants are certain types of antithrombotics, which are often also called blood thinners. Neither thrombolytic drugs, which dissolve clots after they have formed, nor other anti-thrombotics, such as antiplatetelet drugs, are covered in this market.
Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).
Company examples: Bristol Myers Squibb, Bayer, Sanofi, Johnson & Johnson
Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.
Most recent update: Jun 2024
Source: Statista Market Insights
Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.
Most recent update: Mar 2024
The Anti-Coagulants market in Bangladesh has been steadily growing in recent years, driven by various factors such as an aging population and increasing prevalence of cardiovascular diseases.
Customer preferences: In Bangladesh, there is a growing demand for anti-coagulants due to the rising incidence of heart diseases and stroke. Patients are also becoming more aware of the benefits of early detection and treatment, leading to an increase in demand for anti-coagulants.
Trends in the market: One of the major trends in the Anti-Coagulants market in Bangladesh is the shift towards newer oral anticoagulants. These drugs are more effective and have fewer side effects compared to traditional blood thinners such as warfarin. Another trend is the increasing use of anti-coagulants for indications such as deep vein thrombosis and pulmonary embolism.
Local special circumstances: Bangladesh has a large population of elderly people who are at a higher risk of developing cardiovascular diseases. In addition, the country has a high prevalence of risk factors such as obesity, diabetes, and hypertension, which contribute to the growing demand for anti-coagulants. However, there are also challenges such as limited access to healthcare and low awareness about the importance of preventive measures.
Underlying macroeconomic factors: The healthcare sector in Bangladesh has been growing rapidly in recent years, with increasing investment in infrastructure and technology. This has led to improved access to healthcare services and a greater demand for pharmaceutical products. In addition, the government has implemented various initiatives to improve healthcare outcomes, such as the National Health Policy and the Health, Nutrition and Population Sector Program. These factors are expected to drive the growth of the Anti-Coagulants market in Bangladesh in the coming years.
Most recent update: Jun 2024
Source: Statista Market Insights
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Notes: Based on data from IMF, World Bank, UN and Eurostat
Most recent update: Sep 2024
Source: Statista Market Insights